Clinical Trial Update: Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

The trial update reports termination of a Phase 2 study evaluating 90Y-DOTA-hLL2 as consolidation therapy after R-CHOP in patients with diffuse large B-cell lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• 90Y-DOTA-hLL2 (Yttrium-90 labeled DOTA-hLL2)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: B-cell Lymphoma | Phase 2 | Status: TERMINATED